Construction of a stable w/o nano-emulsion as a potential adjuvant for foot and mouth disease virus vaccine.
A stable and bio-compatible w/o nano-emulsion was developed as adjuvant for foot and mouth disease (FMD) vaccine with isopropyl myristate as oil phase, polyglycerol polyricinoleate, and Tween 80 as surfactants. Dissolving Tween 80 in aqueous phase decreased the droplet size and improved stability of the emulsion through narrowing size distribution, increasing viscosity, and reducing the interfacial tension between oil and water. The nano-emulsion was then formulated with inactivated FMD virus and ovalbumin to investigate its potential application as an adjuvant. Compared with commercial ISA-206 adjuvant, the novel w/o nano-emulsion was able to induce both humoral- and cell-mediated immune response.
a State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , Beijing , PR China.|b University of Chinese Academy of Sciences , Beijing , PR China.
Zenghui
Z
Chen
a State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , Beijing , PR China.
Songping
S
Zhang
a State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , Beijing , PR China.|b University of Chinese Academy of Sciences , Beijing , PR China.
Zhengjun
Z
Li
a State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , Beijing , PR China.
Guanghui
G
Ma
a State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , Beijing , PR China.
Zhiguo
Z
Su
D000276:Adjuvants, Immunologic / Q000737:chemistry*; D000818:Animals; D000956:Antigens, Viral / Q000737:chemistry / Q000276:immunology; D001672:Biocompatible Materials / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D004355:Drug Stability; D004655:Emulsions; D005260:Female; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D005990:Glycerol / Q000031:analogs & derivatives / Q000737:chemistry; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D051379:Mice; D049329:Nanostructures; D009821:Oils / Q000737:chemistry; D010047:Ovalbumin / Q000276:immunology; D011136:Polysorbates / Q000737:chemistry; D012277:Ricinoleic Acids / Q000737:chemistry; D014765:Viral Vaccines / Q000276:immunology*; D014783:Viscosity; D014867:Water / Q000737:chemistry
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D001672:Biocompatible Materials; D004337:Drug Carriers; D004655:Emulsions; D009821:Oils; D011136:Polysorbates; D012277:Ricinoleic Acids; D014765:Viral Vaccines; C029243:glyceran polyricinoleic acid ester; D014867:Water; D010047:Ovalbumin; D005990:Glycerol
Adjuvant; foot-and-mouth disease vaccine; polyglycerol polyricinoleate; stability; w/o nano-emulsion